Mitapivat

FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia
Actualités

FDA Grants Orphan Drug Designation to Mitapivat for Treatment of Thalassaemia

Agios Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s first-in-class pyruvate kinase-R (PKR) activator Mitapivat for the treatment of…
Bouton retour en haut de la page